AstraZeneca Cuts Scope 3 Target to 35% as AI Drives R&D Push

AstraZeneca has lowered its 2030 Scope 3 emissions reduction target to 35 percent from 2019 levels, down from a previous goal of 50 percent, while cutting its AZ Forest tree-planting target in half to 100 million trees. The revisions, announced during the company's 2026 Sustainability Update, come alongside genuine progress elsewhere: an 88 percent cut in Scope 1 and 2 emissions since 2019, more than 66 million trees already planted, and a $500 million investment to replace inhaler propellants with a near-zero warming alternative. Chief Sustainability Officer Pam Cheng framed the changes as reflecting business growth and lessons learned rather than reduced ambition.

 

Why the Targets Were Lowered, Not Just Missed

 

The most consequential disclosure is the Scope 3 revision, and the company's explanation is worth examining closely. Cheng said the absolute amount of emissions reduction under the new 35 percent target is the same as under the original 50 percent target, because the original goal was calculated against a smaller revenue base. AstraZeneca is now targeting $80 billion in total revenue and 20 new medicines by 2030, and as the business has grown, the percentage needed to achieve the same absolute cut has fallen.

That explanation is plausible but also illustrates a structural tension in percentage-based climate targets: a company can hit its absolute emissions goal while its published percentage target quietly slips as the business expands, which is precisely what has happened here. Whether investors and analysts read this as a legitimate recalibration or a softening of ambition will likely depend on whether the company continues to report the absolute tonnage reduction figure clearly alongside the percentage, so that growth-driven revisions don't obscure whether real-world emissions cuts are keeping pace.

The tree-planting revision follows a different logic. Cheng said the cut from 200 million to 100 million trees reflects operational lessons since the programme launched and a shift toward prioritising high-quality projects over sheer volume, an argument that a smaller number of well-managed plantings may deliver more durable carbon and biodiversity benefit than a larger number of poorly monitored ones. With more than 66 million trees already planted across 80 species, the company is roughly two-thirds toward the reduced target.

 

Read more: ESG Playbook Launches Reporting Tools for Small and Mid-Sized Businesses

 

The Inhaler Propellant as a Concentrated Decarbonisation Lever

 

The single most significant emissions reduction lever the company described is the transition away from conventional pressurised metered-dose inhaler propellants, which Cheng said account for 26 percent of AstraZeneca's total Scope 3 footprint. That concentration matters enormously for a pharmaceutical company's climate strategy, since it means a single product category, rather than a broad and diffuse set of supply chain activities, drives more than a quarter of the company's indirect emissions.

The $500 million investment in a near-zero global warming potential propellant addresses that concentration directly. The UK approved the new propellant for one AstraZeneca respiratory medicine last year, which the company called a world and industry first, and the transition is now complete across Europe with other regions to follow. Because pMDI emissions are so disproportionately large relative to other Scope 3 categories, successfully completing this transition across the wider product portfolio by 2030 would meaningfully move the needle on the company's overall footprint in a way that more incremental supply chain measures cannot.

 

Explore OneStop ESG Marketplace: AI (Artificial Intelligence)

 

AI as Both an Efficiency Tool and an Emerging Environmental Cost

 

AstraZeneca is deploying artificial intelligence across research, manufacturing and diagnosis, targeting roughly 35 percent productivity improvement and 50 percent faster lead times by 2030 through digital modelling of drug candidates that reduces the need for physical screening. In diagnosis, the company pointed to MILTON, an AI tool trained on UK Biobank data that combines health records with genetic and proteomics data to predict risk for more than 1,000 diseases, in some cases a decade or more before clinical diagnosis, alongside a separate programme with Qure.ai that has completed 5 million AI-enabled chest X-rays across more than 20 countries to improve early lung cancer detection in resource-limited settings.

Cheng also acknowledged directly that AI computing carries its own environmental cost, and said the company is shifting data centre and compute infrastructure toward more energy-efficient, renewable-powered facilities. That acknowledgement is notable because many companies promoting AI-driven efficiency gains do not address the energy consumption of the AI systems themselves, and pairing the productivity narrative with an explicit environmental mitigation plan suggests the company is treating AI's footprint as a genuine consideration rather than an afterthought. On governance, Cheng said public AI tools require formal approval before use, higher-risk systems undergo ongoing validation, and uses prohibited under the EU AI Act are treated as prohibited company-wide regardless of jurisdiction, with more than 50,000 employees having completed internal AI training.

Beyond climate and AI, the company also detailed health equity programmes it says have reached more than 156 million people from underserved communities since 2024, and a health system resilience partnership now active in 37 countries. Sustainability lead Liz Chatwin pointed to concrete operational payoffs from these investments, including a continuous manufacturing technology that cut tablet production time for one hypertension medicine from 20 days to 20 minutes, illustrating how the company frames sustainability measures as delivering business value rather than existing solely as a cost. Whether the revised Scope 3 and forestry targets represent a durable recalibration toward more achievable goals, or the first sign of ambition drifting as 2030 approaches, will become clearer as the company reports progress against both the new targets and the underlying absolute emissions figures in the years ahead.